AMACR and HMWCK as diagnostic tool for confirming prostate adenocarcinoma in needle prostate biopsy
Abstract
Introduction: The histopathological examination is always necessary to diagnose prostate adenocarcinoma but it would be better if the diagnosis can be supported with more accuracy by Immunohistochemistry. This study has been carried out to check usefulness of AMACR and HMCK as diagnostic tool to support diagnosis of prostate adenocarcinoma. AMACR stands for alpha-methylacyl-CoA racemase and HMWCK stand for High molecular weight cytokeratin.
Material and Methods: The study was done in 50 morphological diagnosed prostate adenocarcinoma cases at tertiary care hospital. AMACR and HMWCK immunohistochemistry was done in all these cases. All the data has been plotted in tabulated form and p value calculated for both AMACR and HMWCK using Fischer’s exact and chi-square test.
Results: AMACR shows strong cytoplasmic immunoreactivity in almost all prostate cancer cells while HMWCK shows strong nuclear immunoreactivity in almost all benign prostatic epithelial cells. The p value in both the cases were <0.0001 suggesting strong association of AMACR and HMWCK with prostate cancer cases.
Conclusion: AMACR and HMWCK both can be used to confirm morphologically diagnosed prostate adenocarcinoma cases and it should be used in all cases of prostate carcinoma to confirm the diagnosis by immunohistochemistry.
Downloads
References
Lu-Yao G, Stukel TA, Yao SL. Prostate-specific antigen screening in elderly men. J Natl Cancer Inst. 2003; 95(23):1792-1797. doi: https://doi.org/10.1093/jnci/djg104.
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002; 94(13):981-990. doi: https://doi.org/10.1093/jnci/94.13.981.
Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and over detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-878. doi: https://doi.org/10.1093/jnci/95.12.868.
Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000;60(6):1677-1682.
Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res., 2001;61(12):4683-4688.
Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. Alpha-methylacyl coenzyme Aracemase as a tissue biomarker for prostate cancer. JAMA. 2002; 287(13):1662-1670. doi: https://doi.org/10.1001/jama.287.13.1662.
Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001; 25(11):1397-1404.
Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157(6):1769-1775. doi: https://doi.org/10.1016/S0002-9440(10)64814-6.
Parsons, J. K., Gage, W. R., Nelson, W. G., and De Marzo, A. M. Expression of p63in normal, neoplastic and preneoplastic human prostate tissues. Urol. 2001;58(4):619-624. doi: https://doi.org/10.1016/S0090-4295(01)01311-5.
Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002;15(12):1302-1308. doi: https://doi.org/10.1097/01.MP.0000038460.95912.6E.
Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26(7):926-931.
Beach R, Gown AM, De Peralta-Venturina MN, Folpe AL, Yaziji H, Salles PG, et al. P504Simmunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26(12):1588-1596.
Yang XJ, Wu CL, Woda BA, Dresser K, Tretiakova M, Fanger GR, et al. Expression of alpha-methylacyl-CoAracemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol. 2002;26(7):921-925.
Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H, et al. Alpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol. 2002;161(3):841-848. doi: https://doi.org/10.1016/S0002-9440(10)64244-7.
Epstein JI, Potter SR. The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J. Urol. 2001;166(2):402-410.
OAI - Open Archives Initiative
